Forum Agenda

Peptide Drug R&D Frontier Session

Stay tuned

GLP‑1 R&D Journey and Outlook
Wang Qinghua: Founder, Chairman & CEO, Guangzhou Innogen Pharmaceutical Group Co., Ltd.


Cyclic Peptide Discovery Integrating mRNA Display and AI
Cui Haifeng: CSO, Shanghai Highline Therapeutics, Inc.


CMC for Peptide Drugs
WuXi AppTec Co., Ltd.


AI‑Designed Cyclic Peptide Drugs to Tackle Undruggable Targets
Zhang Genwei: Peptide R&D Lead, XtalPi Holdings Limited


TBD
Wu Fangzhou: Head of Peptide Biology Department, Hengrui Medicine | Tuojie Biomedical (Invited)


Peptide Drug Screening and Evaluation – From GLP‑1 to Multi‑Target Agonists
Wang Xinyuan: Technical Manager, Application Business, Revvity China

 

Panel Discussion:
1.Beyond GLP‑1 – Where is the next hundred‑billion‑dollar opportunity for peptide drugs?
2.How can China's innovative drug industry define the value of the peptide industry chain?
3.China's peptide innovation going global – Opportunities, challenges, and future directions?

Liu Jiang (Moderator): Global Vice President & General Manager, Greater China, Revvity
Cao Chunlai: CEO, Federal Biotechnology (Zhuhai Hengqin) 
Chen Xiaoxin: Vice President, Guangdong Zhongsheng Pharmaceutical ; Co‑Founder, Chairman & CEO, Guangdong Zhongsheng Ruichuang Biological Technology
Huang Baohua: Founder & CEO, Coherent Biopharma
Zhai Peng: Co‑Founder, Senior Vice President & Head of CMC and Manufacturing, QL Biopharm
Zhang Yingjun: Chairman, Sunshine Lake Pharma